FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283373835> ?p ?o ?g. }

• W4283373835 endingPage "3088" @default.
• W4283373835 startingPage "3088" @default.
• W4283373835 abstract "For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome. For this purpose, the BM MRD status and EC/MSC regeneration profile were analyzed by multiparameter flow cytometry (MFC) in 16 control BM (10 children; 6 adults) and 1204 BM samples from 347 children and 100 adult BCP-ALL patients studied at diagnosis (129 children; 100 adults) and follow-up (824 childhood samples; 151 adult samples). Patients were grouped into a discovery cohort (116 pediatric BCP-ALL patients; 338 samples) and two validation cohorts (74 pediatric BCP-ALL, 211 samples; and 74 adult BCP-ALL patients; 134 samples). Stromal cells (i.e., EC and MSC) were detected at relatively low frequencies in all control BM (16/16; 100%) and in most BCP-ALL follow-up samples (874/975; 90%), while they were undetected in BCP-ALL BM at diagnosis. In control BM samples, the overall percentage of EC plus MSC was higher in children than adults (p = 0.011), but with a similar EC/MSC ratio in both groups. According to the MRD status similar frequencies of both types of BM stromal cells were detected in BCP-ALL BM studied at different time points during the follow-up. Univariate analysis (including all relevant prognostic factors together with the percentage of stromal cells) performed in the discovery cohort was used to select covariates for a multivariate Cox regression model for predicting patient DFS. Of note, an increased percentage of EC (>32%) within the BCP-ALL BM stromal cell compartment at day +78 of therapy emerged as an independent unfavorable prognostic factor for DFS in childhood BCP-ALL in the discovery cohort—hazard ratio (95% confidence interval) of 2.50 (1−9.66); p = 0.05—together with the BM MRD status (p = 0.031). Further investigation of the predictive value of the combination of these two variables (%EC within stromal cells and MRD status at day +78) allowed classification of BCP-ALL into three risk groups with median DFS of: 3.9, 3.1 and 1.1 years, respectively (p = 0.001). These results were confirmed in two validation cohorts of childhood BCP-ALL (n = 74) (p = 0.001) and adult BCP-ALL (n = 40) (p = 0.004) treated at different centers. In summary, our findings suggest that an imbalanced EC/MSC ratio in BM at day +78 of therapy is associated with a shorter DFS of BCP-ALL patients, independently of their MRD status. Further prospective studies are needed to better understand the pathogenic mechanisms involved." @default.
• W4283373835 created "2022-06-25" @default.
• W4283373835 creator A5000288435 @default.
• W4283373835 creator A5006790084 @default.
• W4283373835 creator A5007036560 @default.
• W4283373835 creator A5013720867 @default.
• W4283373835 creator A5014791873 @default.
• W4283373835 creator A5020812442 @default.
• W4283373835 creator A5027341200 @default.
• W4283373835 creator A5028102225 @default.
• W4283373835 creator A5028824291 @default.
• W4283373835 creator A5039412423 @default.
• W4283373835 creator A5041188992 @default.
• W4283373835 creator A5043074749 @default.
• W4283373835 creator A5044371990 @default.
• W4283373835 creator A5048766729 @default.
• W4283373835 creator A5055210686 @default.
• W4283373835 creator A5058731031 @default.
• W4283373835 creator A5062827809 @default.
• W4283373835 creator A5064746136 @default.
• W4283373835 creator A5069240484 @default.
• W4283373835 creator A5071200296 @default.
• W4283373835 creator A5077705169 @default.
• W4283373835 creator A5083769556 @default.
• W4283373835 creator A5088409474 @default.
• W4283373835 date "2022-06-23" @default.
• W4283373835 modified "2023-10-04" @default.
• W4283373835 title "Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome" @default.
• W4283373835 cites W1262816711 @default.
• W4283373835 cites W1499446950 @default.
• W4283373835 cites W165520502 @default.
• W4283373835 cites W1774142096 @default.
• W4283373835 cites W1801876107 @default.
• W4283373835 cites W1938140712 @default.
• W4283373835 cites W1966898047 @default.
• W4283373835 cites W1970504500 @default.
• W4283373835 cites W1973751980 @default.
• W4283373835 cites W1975612301 @default.
• W4283373835 cites W1979630015 @default.
• W4283373835 cites W1983307337 @default.
• W4283373835 cites W1985823023 @default.
• W4283373835 cites W1987180287 @default.
• W4283373835 cites W1987538151 @default.
• W4283373835 cites W1988508537 @default.
• W4283373835 cites W1991069555 @default.
• W4283373835 cites W1991358041 @default.
• W4283373835 cites W1998401408 @default.
• W4283373835 cites W2000266274 @default.
• W4283373835 cites W2005054221 @default.
• W4283373835 cites W2020622102 @default.
• W4283373835 cites W2024968355 @default.
• W4283373835 cites W2025371271 @default.
• W4283373835 cites W2035197415 @default.
• W4283373835 cites W2044703599 @default.
• W4283373835 cites W2045032252 @default.
• W4283373835 cites W2048369602 @default.
• W4283373835 cites W2050152294 @default.
• W4283373835 cites W2065499297 @default.
• W4283373835 cites W2067347835 @default.
• W4283373835 cites W2067459417 @default.
• W4283373835 cites W2070007455 @default.
• W4283373835 cites W2075139424 @default.
• W4283373835 cites W2077469955 @default.
• W4283373835 cites W2084778800 @default.
• W4283373835 cites W2087296000 @default.
• W4283373835 cites W2105345844 @default.
• W4283373835 cites W2112711017 @default.
• W4283373835 cites W2115533320 @default.
• W4283373835 cites W2117100825 @default.
• W4283373835 cites W2123424761 @default.
• W4283373835 cites W2124660937 @default.
• W4283373835 cites W2125277492 @default.
• W4283373835 cites W2130122821 @default.
• W4283373835 cites W2132827894 @default.
• W4283373835 cites W2134091917 @default.
• W4283373835 cites W2137984061 @default.
• W4283373835 cites W2138621885 @default.
• W4283373835 cites W2139928380 @default.
• W4283373835 cites W2147852317 @default.
• W4283373835 cites W2148631711 @default.
• W4283373835 cites W2151069914 @default.
• W4283373835 cites W2151645052 @default.
• W4283373835 cites W2159137057 @default.
• W4283373835 cites W2161096609 @default.
• W4283373835 cites W2162433799 @default.
• W4283373835 cites W2162906664 @default.
• W4283373835 cites W2172250118 @default.
• W4283373835 cites W2293196298 @default.
• W4283373835 cites W2313577290 @default.
• W4283373835 cites W2317633242 @default.
• W4283373835 cites W2551657950 @default.
• W4283373835 cites W2558502346 @default.
• W4283373835 cites W2563984765 @default.
• W4283373835 cites W2590038973 @default.
• W4283373835 cites W2616184417 @default.
• W4283373835 cites W2617225956 @default.
• W4283373835 cites W2667331047 @default.
• W4283373835 cites W2780941043 @default.

• next